Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30196114 | 1.00 | NAMPT (0.50) | NAMPTCYP17A1SYKRAB9ABRD4 | |
| SCHEMBL23771038 | 0.84 | NAMPT (0.48) | NAMPTCYP17A1SYKRAB9ATOP2A | |
| SCHEMBL22574157 | 0.81 | JAK2 (0.43) | NAMPTRAB9AJAK2JAK1TYK2 | |
| SCHEMBL31038470 | 0.80 | NAMPT (0.46) | NAMPTCYP17A1RAB9AJAK2JAK1 | |
| SCHEMBL4093611 | 0.80 | NAMPT (0.46) | NAMPTCYP17A1RAB9AJAK2JAK1 | |
| SCHEMBL14428036 | 0.80 | NAMPT (0.54) | NAMPTCYP17A1SYKRAB9ATOP2A | |
| SCHEMBL6756707 | 0.75 | NAMPT (0.60) | NAMPTCYP17A1RAB9ABCL2 | |
| SCHEMBL29674394 | 0.75 | NAMPT (0.49) | NAMPTCYP17A1SYKTOP2ATOP2B | |
| SCHEMBL349933 | 0.75 | NAMPT (0.80) | NAMPTRAB9A | |
| SCHEMBL12735928 | 0.75 | NAMPT (0.49) | NAMPTCYP17A1SYKTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11535635-B2 | — | — | 2022-12-27 | — | — | US | disclosed |
| US-20210253600-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PI4KA | NAMPT 1015/4885CYP17A1 3667/4885SYK 2210/4885 |
| US-11535635-B2 | — | PIP5K1A, PI4K2A, PIP5K1B | NAMPT 766/4885CYP17A1 1438/4885SYK 4559/4885 |
| US-20210253600-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PI4KA | NAMPT 1015/4885CYP17A1 3667/4885SYK 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.